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BASP1 is a neuronal signalling protein that was found to be a corepressor of the 
developmental transcription factor Wilms’ tumour 1 (WT1). Both BASP1 and WT1 
are involved in several different types of cancer and can act as both tumour 
suppressors and oncogenes. Together, they form the BASP1/WT1 repressive 
complex which can inhibit the transcription of WT1 target genes. Recent studies in 
understanding the repressive mechanism of this complex showed that BASP1 
facilitates the removal of activatory histone marks (H3K4me3 and H3K9ac) and the 
placement of repressive histone marks (H3K9me3 and H3K27me3). EZH2, a core 
subunit of the polycomb (PRC2) complex, was found to be recruited to the promoter 
region of WT1 target genes by BASP1. EZH2 is a histone methyltransferase which 
places H3K27me3 marks on gene promoters. Whether or not EZH2 is the enzyme 
that places the BASP1-dependent H3K27me3 mark and is involved in the 
transcriptional repression mechanism of BASP1 is not known. 
This study used three different EZH2 inhibitors to examine the role of EZH2 in 
BASP1-dependent transcriptional repression in two different cell lines. The work 
revealed that EZH2 is responsible for placing BASP1-dependent H3K27me3 marks 
on the promoters of WT1 target genes. However, the BASP1/WT1 complex exhibited 
different requirements for EZH2 activity in transcriptional repression depending on 
the specific target gene.  
The effects of EZH2 inhibition on BASP1-dependent suppression of cancer cell 
growth was also studied. The results showed that, in the absence of EZH2, K562 
cells had a decreased growth rate and MCF7 cells showed decreased 
tumorigenicity, suggesting that the BASP1/WT1 complex works with EZH2 to repress 
growth-promoting genes.  
The findings indicate that the BASP1/WT1 complex employs multiple mechanisms to 
mediate gene repression. The results suggest that EZH2 plays a role in the function 
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 One of the first tumour suppressor genes (TSG) to be identified and cloned 
was the transcription factor Wilms’ Tumour 1 (WT1). It was discovered due to its 
involvement in the paediatric kidney cancer Wilms’ Tumour (WT) 1.WT is one of the 
most common childhood solid cancers, affecting 1 in every 10 000 children2. This is 
because WT1 plays a central role ins regulating kidney development during 
embryogenesis and was found to be mutated in 15% of WT cases. Interest in WT1 
arose when it was found that as a transcription factor it can affect a range of cell 
processes. WT1 controls the expression of genes that affect cell apoptosis, growth 
and differentiation3. The ability of WT1 to control the expression of genes involved in 
both cell growth and cell death relies on its ability to act as both an activator and 
repressor of transcription, depending on the cofactors it interacts with4. 
1.1.1 WT1 Structure, isoforms and function 
 The WT1 gene is found at the chromosome locus 11p13  and is 
approximately 50kb5. As seen in Figure 1.1, WT1 is made up of four zinc fingers at 
its C-terminus that allow it to bind to DNA and a proline and glutamine-rich region at 
its N-terminus 6. It has a transcriptional repression domain between residues 71-180 
and a transcriptional activation domain between residues 180-250 that act 
independently to allow WT1 to activate or repress a range of target genes7. The WT1 
gene includes 10 exons that can undergo alternative splicing, use of alternative 
translation start sites and RNA editing to generate over 24 different isoforms8. Two of 
the most studied isoforms in mammals arise from alternative splicing of exon 9  
which leads to either the removal or addition of a three amino acid sequence made 
up of  lysine, threonine and serine (KTS), between zinc fingers 3 and 4 9. These two 
isoforms are highly conserved in all vertebrates. The +KTS isoform of WT1 is known 
to bind to RNA with higher affinity and has an important role during gonad 
development 3,10. The -KTS isoform of WT1 is known to bind to DNA with higher 
affinity and has an important role in kidney development and podocyte differentiation. 
Exon 5 of the WT1 gene also commonly undergoes alternative splicing resulting in 
the addition of a 17 amino acid sequence (+17AA). This WT1 isoform is only found in 
mammalian cells and its function is not yet known11. WT1 can also undergo several 
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post-translational modifications. It can be SUMOylated at two lysine residues (Lys73 
and Lys177) located within the transcriptional repression domain at the N-terminus12. 
The effect of this modification is not yet known however it has been proposed to 
affect the association of WT1 with its cofactors that are also SUMOylated. WT1 can 
also be phosphorylated at serine 365 within zinc finger 2 by protein kinase A (PKA) 
and at serine 393 within zinc finger 3 by protein kinase C (PKC) 13. These 
phosphorylation events decrease the ability of WT1 to regulate transcription by 
preventing it from binding to DNA 14. 
  
 
 Due to the ability of WT1 to act as both a transcriptional repressor and 
activator, the mechanisms by which it acts as a transcriptional regulator are complex 
and depend on the cofactors interacting with WT14. CBP is a histone acetyl 
transferase (HAT) that interacts with WT1 to promote transcriptional activation of 
target genes15. Brain acid soluble protein 1(BASP1) associates with WT1 to promote 
transcription repression by recruiting histone deacetylases (HDAC)16. WT1 can also 
bind to other DNA-binding proteins such as p53, which allows it to be recruited to 
target gene promoters17. The main way WT1 localises to promoters, however, is by 
directly binding to the DNA. 
The ability of WT1 to act as transcriptional regulator by either activating or 
repressing genes underlies its fundamental roles during embryogenesis. WT1 is 
Figure 1.1: A schematic of the primary structure of the WT1 protein. The sites where alternative 
splicing occurs are shown in orange (+17AA and +KTS). The sites of post-translational 
modifications are shown as SUMOylation and phosphorylation. The transcriptional repression 
domain is shown in red (R) and the transcriptional activation domain is shown in green (A). The 4 




involved in the normal development of the kidneys, heart, gonads, spleen and many 
other organs18. Several developmental disorders can occur due to mutation of WT1 
which emphasises its important functions during development. Denys-Drash 
syndrome leads to severe developmental abnormalities such as hermaphroditism 
and renal failure and can be caused by intergenic mutations in exons 8 and 9 of WT1 
where the DNA-binding domains are found19. Heterozygous deletions of WT1 
resulting in loss of WT1 function can result in the development of WT, aniridia, 
genitourinary abnormalities and mental retardation, also known as WAGR 
syndrome20.Developmental abnormalities are not the only disorders associated with 
WT1. WT1 mutations have also been associated with a number ofr different cancers 
including lung, prostate, leukaemias and Wilms’ tumour. 
1.1.2 WT1 in cancer  
WT1 was first identified to be involved in cancer in Wilms’ Tumour as a TSG. 
In 10-15% of Wilms’ tumours WT1 is inactivated which results in increased cell 
proliferation and survival1. WT1 has since also been found to act as an oncogene in 
adult cancers where it is expressed in tissues where it is not normally found such as 
the colon, breast and brain21–24. Overexpression of WT1 promotes angiogenesis and 
vascularisation and in leukaemias such as AML, ALL and CLL, high levels of WT1 
are associated with a poor prognosis25. 
1.2 BASP1 
 BASP1 was originally isolated from brain cells as a member of the neuronal 
signalling protein family and was later found to be expressed in many other neuronal 
cell types26. It was then found that BASP1 is in fact widely expressed including at 
sites such as the kidney, spleen and gonads where there are also high levels of WT1 
expression. Further studies into the relationship between BASP1 and WT1 found 
that BASP1 acts a cosuppressor to WT1 by binding to it and so preventing 
transcription of WT1 target genes16. 
1.1.3 BASP1 Structure and Properties  
BASP1 is a highly charged protein that was initially found to be cytoplasmic 
and membrane localised26. Subsequent studies have since shown that BASP1 is 
also be present in the nucleus. It belongs to a family of neuronal signalling proteins 
along with GAP43 and MARCKS which are found in high amounts in nerve cells27 . 
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These proteins share similar properties like the ability to bind to cell membrane 
phospholipids, but their primary structures are very different. As seen in Figure 1.2, 
BASP1 has a membrane binding domain at its N-terminus where a myristoyl group 
can be added on the α-amino group of the glycine residue at position 2. Myristylation 
of BASP1 occurs co-translationally and it allows this hydrophilic protein to interact 
with cell membranes28. It also has a basic region which helps BASP1 to interact with 
acidic phospholipids like phosphatidylinositol 4,5-biphosphate (PIP2) and Ca2+ bound 
calmodulin. The first N-terminal 18 amino acid sequence of BASP1 contains the 
glycine on which the myristoyl group is added as well as a cholesterol recognition 
amino acid consensus (CRAC) domain which allows BASP1 to interact with 
cholesterol29. This region of BASP1 is highly conserved across vertebrates, 
highlighting the importance of PIP2 and cholesterol interactions of BASP126. BASP1 
has 3 PEST domains indicative of a high turnover protein which are also highly 
conserved30. PKC can phosphorylate BASP1 at multiple serine residues. 
Phosphorylation at Ser6 can disrupt the positive charge of the N-terminus and 
results in the destabilisation of BASP1-lipid interactions 28. Many of the other 
phosphorylation sites are found within the PEST sequences which suggests that 
PKC has a role in regulating BASP1 stability. BASP1 can also be sumoylated at 
specific lysine residues and this causes its redistribution from chromatin to the 
nuclear matrix10.        
 
Figure 1.2: The structure of the BASP1 protein. BASP1 contains an N-terminal membrane 
binding domain (MBD), a basic region (BR) and a nuclear localisation sequence (NLS) at the N-
terminus. This region forms the binding site for PIP2. The N-terminal glycine residue (in red) is 
myristoylated. The 3 PEST domains are shown in yellow. BASP1 is phosphorylated at the 
indicated serine residues and sumoylated at the indicated lysine residues. 
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1.2.2 BASP1 in cancer 
 BASP1 is involved in many different types of cancer where it frequently acts 
as a TSG27 .  In thyroid cancer, overexpression of BASP1 decreases cancer cell 
growth by causing G1 cell cycle arrest via Cyclin D1 inhibition and p21 and p27 
activation31. Overexpression of BASP1 was also seen to prevent cancer cell 
migration by inhibiting β-catenin and E-cadherin. This suggests BASP1 has a role as 
a TSG in thyroid cancer and a poor prognosis has been associated with low levels of 
BASP1. In hepatocellular carcinomas BASP1 expression is significantly decreased 
by promoter methylation in the cancer cells compared to normal cells32. In breast 
cancer BASP1 can act as a transcriptional cosuppressor of ERα, which is a hormone 
receptor involved in regulating proliferation and differentiation genes33. This 
interaction is enhanced by treatment of breast cancer cells with tamoxifen (a drug 
normally given as part of breast cancer treatment). BASP1 can enhance the growth 
inhibitory effect of tamoxifen through its interaction with ERα3334. BASP1 was also 
recently shown to act as an oncogene in cervical cancer where it becomes 
upregulated leading to increased cell proliferation34.  
1.2.3 BASP1/WT1 in differentiation 
With the ability to repress several genes, the BASP1/WT1 complex was also 
found to be involved in several differentiation pathways by controlling the expression 
of the genes involved. The BASP1/WT1 complex can change the differentiation 
pathway of K562 leukaemia cells following PMA treatment25. K562 express 
endogenous WT1 but do not express BASP1 and will normally differentiate into 
megakaryocytes when treated with PMA. However, K562 cells engineered to 
express BASP1 will differentiate into elongated neuronal-like cells. This happens 
because BASP1 can alter the PMA-induced expression profile away from 
megakaryocyte-associated genes towards genes with neuronal function. The 
BASP1/WT1 complex is also involved in the differentiation pathway of taste receptor 
cells. During development of the taste receptor cells only WT1 is expressed but once 
they begin to differentiate, they start to express BASP1. BASP1 expression is 
maintained in adult taste buds where it colocalises with WT1 at the promoter regions 
of target genes. BASP1  expression in mature taste cells is essential for taste 
detection35. BASP1 inhibits the expression of LEF1 of the Wnt pathway and PTCH1 
of the Shh pathway, which are both WT1 target genes. The expression of these 
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genes is normally associated with the progenitor cells and thus their repression by 
the WT1/BASP1 complex is needed to maintain the differentiation state of taste 
receptor cells36,37. A similar pattern has been observed in stem cells where 
multipotency is maintained when WT1 is expressed alone and when BASP1 is 
switched on  multipotency is blocked and stem cells are driven to differentiate38. 
These effects of BASP1 were studied using induced pluripotent stem cells (iPSCs) 
made by transient expression of Oct4, Sox2, Klf4 and c-Myc, also known as the 
OSKM cocktail39. Antibody-mediated inhibition of BASP1 was found to be able to 
replace the need for Sox2 in the OSKM cocktail, further confirming that the presence 
of BASP1 inhibits the reprogramming of cells. Further studies found that this was 
because BASP1 repressed the expression of the WT1 target gene Lin28. Lin28 is an 
RNA-binding protein that can promote pluripotency by regulating Let-7 miRNA40. 
These results suggest an interesting interplay between BASP1 and WT1 during the 
development of stem cells and could have potential therapeutic roles. 
1.2.4 BASP1/WT1 Repressive Complex 
The presence of BASP1 at sites of high WT1 activity suggested that these two 
proteins work together to ensure normal embryonic development. Genome-wide 
studies have shown that BASP1 can regulate over 1000 different genes in K562 
cells. Moreover, BASP1 regulates the activity of other transcription factors like ERα.  
However it has mostly been studied as a cosuppressor of WT1 and therefore it is 
best understood as a part of the BASP1/WT1 repressive complex25. In recent years it 
has been shown that BASP1 can bind to the suppression domain of WT1 and 
mediate repression of WT1 target genes by recruiting a number of different cofactors 
at target gene promoters16. The recruitment of most cofactors by BASP1 requires the 
myristoyl group located at its N-terminus which allows BASP1 to interact with PIP2 
and so recruit additional cofactors28. A mutant BASP1 derivative where the myristoyl 
acceptor glycine is replaced with an alanine (BASP1 G2A) cannot act as a 
transcriptional cosuppressor of WT1. In Figure 1.3 it is shown that the BASP1/WT1 
repression complex recruits HDAC1 which removes negatively charged acetyl 
groups from histone sites like histone 3 lysine 9 (H3K9ac)28. It also recruits prohibitin 
which in turn recruits BRG1 of the ATP-dependent chromatin remodelling SWI/SNF 





Recent studies using the BASP1 G2A mutant derivative showed that 
myristoylation of BASP1 is required to deacetylate histone H3K9 at the promoter of 
WT1 target genes. This action of BASP1 is therefore lipid dependent43. It was also 
shown that BASP1 can also remove methyl groups from lysine 4 of histone 3 
(H3K4me3) which are also activatory marks. This action is also lipid dependent. 
Additional to removing these activation marks, BASP1 can also add repressive 
marks such as methyl groups on histone 3 lysine 27 (H3K27me3) and on histone 3 
lysine 9 (H3K9me3) as can be seen in Figure 1.443. The addition of these repressive 
marks was found to be supported by the G2A mutant BASP1, indicating that this 
action by BASP1 is lipid independent.  
Figure 1.3: Removal of histone acetyl groups by the BASP1/WT1 complex. (A) The WT1-CBP 
activator complex. WT1 interacts with the histone acetyl transferase CBP to placeadd acetylation 
marks on gene promoters and activate gene expression. (B) the WT1-BASP1 repressor complex. 
BASP1 binds to WT1 and recruits PIP2, HDAC1, Prohibitn and BRG1 on gene promoters through its 






1.2.5 BASP1/WT1 lipid independent transcriptional repression 
BASP1 was first shown to be involved in the placement of repressive 
chromatin marks, specifically H3K27me3 at the Wnt4 locus, during the differentiation 
of epicardial cells 44. This locus is regulated by the BASP1/WT1 complex and 
controls epithelial-mesenchymal transition (EMT) and the generation of  progenitor 
cardiovascular cells45. As mentioned above, BASP1 has also been observed to add 
H3K27me3 marks as well as H3K9me3 marks on the promoter regions of WT1 target 
genes and this action is lipid independent. The addition of repressive marks however 
is not sufficient to repress transcription of these genes43. The BASP1 G2A mutant 
does not repress transcription of these genes despite being shown to be able to 
place H3K27me3 marks. These results demonstrate that the removal of activatory 
marks is required for transcriptional repression by BASP1. However, it is not yet 
known if the addition of repressive marks is essential for BASP1 to carry out its role 
as a cosuppressor of WT1. Sites that have both activatory and repressive marks 
present are known as bivalent and are associated with embryonic stem cells46. The 
activatory marks are known to be removed by HDAC1 and prohibitin, however it is 
Figure 1.4: The BASP1/WT1 complex effect on histone chromatin marks. The WT1-BASP1 
complex can remove activatory marks H3K9ac and H3K4me3 and this process is lipid-dependent 
because BASP1 needs to be myristoylated. BASP1 can place repressive marks H3K27me3 and 
H3K9me3 and this process is lipid independent because BASP1 does not need to be 
myristoylated. 
Formatted: Font: Not Bold
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unclear how the repressive methylation marks are added. The enhancer of zeste 
homologue 2 (EZH2) subunit of the Polycomb repressive complex 2 (PRC2) is 
widely known for placing H3K27me3 marks as well as H3K9me3 marks47. Further 
studies using Chromatin Immunoprecipitation (ChIP) experiments showed that EZH2 
is in fact recruited to the promoter regions of WT1 target genes in cells expressing 
BASP143. BASP1-G2A cells can also recruit EZH2 indicating that, like the addition of 
repressive marks, this process is independent of BASP1 lipidation. These findings 
suggest that the addition of repressive marks by BASP1 might be mediated by the 
PRC2 complex.  
1.3 EZH2 
1.3.1 PRC2 Structure and Function 
EZH2 is the main enzymatic subunit of PRC2 that acts as a histone 
methyltransferase to catalyse the mono-, di- and tri-methylation of H3K2748. PRC2 
belongs to a family of Polycomb group (PcG) proteins originally identified in Drosophila 
which are chromatin-associated factors that have an important role in maintaining the 
transcriptionally silent state of genes during early development49. PRC2 is essential 
during embryonic development as it targets and represses developmental genes in 
embryonic stem cells (ESCs) to maintain pluripotency50,51.EZH2 is a core subunit of 
PRC2 alongside Suppressor of Zest 12 (SUZ12) and embryonic ectoderm 
development (EED)52. EZH2 can be replaced by its homologue EZH1 as the catalytic 
subunit of PRC2 and in fact EZH2 is only expressed in actively dividing cells whereas 
EZH1 is ubiquitously expressed making it the most abundant subunit53–55. PRC2-
EZH1 and PRC2-EZH2 exhibit different levels of histone methyltransferase activity, 
with PRC2-EZH2 showing higher levels of activity and so PRC2 is able to switch 
between EZH1 and EZH2 based on the differentiation state of the cell55,56. PRC2-
EZH2 was found to have a more important role in actively dividing cells whereas 
PRC2-EZH1 was found to have a more important role in cells completing the 
differentiation process. The three core subunits are essential for PRC2 activity and if 
deleted they are embryonic lethal in mice and flies57. PRC2 can also interact with other 
factors to produce different subcomplexes which have been subcategorised in two 
main subtypes, PRC2.1 and PRC2.258. PRC2 can interact with PCL homologues 
PCL1-3 and EPOP or PALI to form the PRC2.1 subtype or it can interact with JARID2 
and AEBP2 to from the PRC2.2 subtype. Both subtypes also interact with the histone-
18 
 
binding protein RBBP46/4859. It was suggested that the two different PRC2 subunits 
target different genes but ChIP-seq studies have shown that they have overlapping 
target sites suggesting that the two subunits work together to recruit the core PRC2 
subunits60–63. Another member of the PcG proteins is PRC1 which has distinct 
enzymatic activities to PRC2 and is responsible for catalysing the monoubiquitination 
of Lysine 119 on histone H2A (H2AK119ub)64. PRC1 and PRC2 have been observed 
to have overlapping genomic binding patterns and so are thought to work together to 
establish transcriptional repression65,66. 
1.3.2 EZH2 in cancer 
 Multiple studies have confirmed that EZH2 plays an important role in the 
development of many cancers67. In prostate, breast, bladder and endometrial cancer 
EZH2 is overexpressed which is associated with a more aggressive progression of the 
cancer and a poor prognosis68,69. In cancer cell lines EZH2 has been shown to be 
essential for their proliferation and so cancers that ectopically express EZH2 are 
considered to have a proliferative advantage70. Additional to being overexpressed, 
EZH2 can undergo numerous gain-of-function mutations that can promote 
tumorigenesis. Point mutations affecting the SET domain of EZH2 result in increased 
H3K27me3 and have been identified in 7-12% of follicular lymphomas 71,72. Similarly, 
point mutations at EZH2 alanine residues within its catalytic SET domain result in 
increased H3K27me3 and have been identified in non-Hodgkin’s lymphomas73,74. 
Corresponding to its role in normal ESCs, EZH2 was found to be essential for 
maintaining cancer stem cells in breast cancer75. EZH2 has also been found to 
promote cancer development when it loses its antagonistic factors76. In malignant 
rhabdoid tumours it was found that SNF5 was lost, a core subunit of the SWI/SNF 
complex that normally antagonises EZH2 activity77. These studies have suggested an 
oncogenic role for EZH2 however, there have been studies that also suggest a tumour-
suppressive role of EZH2. Deletion, nonsense and missense mutations of EZH2 have 
been identified in some myeloproliferative neoplasms78. Loss-of-functions mutations 
have also been identified in T cell acute lymphoblastic leukaemia79. Due to the vast 
evidence that EZH2 can act as an oncogene in some cancers, many EZH2 inhibitors 
have been developed with hopes to proceed to clinical trials and provide a new 
treatment for many cancer patients80. These inhibitors include UNC1999, GSK126 and 
GSK343 which are used in this study. 
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 1.3.3 EZH2 and the BASP1/WT1 complex 
 As mentioned previously, EZH2 was recently found to be recruited to the 
promoter of WT1 target genes in a BASP1-dependent manner43. These results are 
shown in Figure 1.5 where K562 cell line derivatives were used. K562 cells are a 
chronic myelogenous leukaemia (CML) cell line that does not express endogenous 
BASP1 but does express endogenous WT1. Figure 1.5 shows the ChIP assays carried 
out to study the recruitment of EZH2 to WT1 target gene promoters. The results show 
that EZH2 recruitment at WT1 target genes occurs at low levels in V-K562 cells (K562 
cells transfected with an empty vector so they do not express BASP1). B-K562 cells 
(cells transfected with vector expressing wild-type BASP1) show enhanced 
recruitment of EZH2 to the promoters. G-K562 cells (cells transfected with vector 
expressing G2A-mutant BASP1) also show enhanced recruitment of EZH2. The 
results suggest that EZH2 is recruited by BASP1 in a lipid-independent manner as 
was referred to in Figure 1.4 and so EZH2 is thought to be responsible for placing 






Figure 1.5: BASP1 can recruit EZH2 to WT1 target gene promoters. ChIP experiments showed that 
EZH2 localises to the promoter regions of WT1 target genes AREG, ETS-1, VDR and JUNB in K562 
cells. Expression of BASP1 or BASP1 G2A in K562 cells enhances the recruitment of EZH2. *p<0.05 by 
Student’s t test.40 
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1.4 Project aims 
 This study aims to provide a better understanding of the transcriptional 
regulation mechanisms carried out by the BASP1/WT1 complex. Previous data from 
the lab have shown that EZH2 is recruited to the promoters of WT1 target genes by 
BASP1 and that this coincides with the placement of H3K27me3/H3K9me3 marks. 
However, it is not known if EZH2 is involved in BASP1-mediated transcriptional 
repression or if its recruitment is a coincidental. This study aims to provide a better 
understanding of the potential role of EZH2 in BASP1/WT1-mediated transcriptional 
repression. The role of EZH2 will be investigated in the K562 cell line derivative 
system and in MCF7 cells, a breast cancer cell line expressing endogenous BASP1 
and WT1. The first focus of this study was to determine if EZH2 has a role in the 
proliferation of K562 and MCF7 cells and if this was affected by the expression level 
of BASP1. The second focus of the study was to understand the role of EZH2 in 
WT1/BASP1-mediated transcriptional repression. The study makes use of specific 
EZH2 inhibitors, UNC1999, GSK343 and GSK126 which are S-adenosyl-L- 
methionine (SAM)-competitive inhibitors of EZH281–83. SAM is a universal methyl 
donor involved in the catalytic reaction of histone methyltransferases. The effects of 
the EZH2 inhibitors will be studied using a group of WT1 target genes, Amphiregulin 












2.Methods and Materials 
2.1 General Reagents 
From Thermo Fisher Scientific: 
Ethanol, Methanol, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
Sodium Dodecyl Sulfate (SDS), Tween, Bromophenol Blue, Magnesium Chloride, 
Ethylene diamine tetraacetic acid (EDTA), Tris Ammonium Persulfate, Glycerol, 
Glycine, 37% Formaldehyde, Tris Acetate-EDTA (TAE), Ammonium Persulfate 
(APS) 
From Sigma Life Science: 
Phosphate buffered saline (PBS), Triton X-100, Lithium Chloride, Sodium 
Deoxycholate 
Sodium Chloride and Potassium Chloride are from VWR Chemicals. Nonidet P-40 
(NP-40) is from Millipore. Dithiotreitol (DTT) is from Santa Cruz Biotechnology. 30% 
Acrylamide/Bis Solution is from BIO-RAD. Tetramethylethylenediamine (Temed) is 
from Flowgen Bioscience. Dimethyl Sulfoxide (DMSO) is from Corning Mediatech.  
2.2 Tissue Culture  
Stable K562 cell lines were previous prepared by transfecting with pc-DNA3 
plasmids that were either empty or driving expression of wtBASP1 as described 
previously by Goodfellow et al, 201125. Cells were maintained in Rosewell Park 
Memorial Institute (RPMI) 1640 media supplemented with 10% Foetal Bovine Serum 
(FBS), 1% Penicillin-Streptomycin (Pen-Strep) and 1% L-Glutamine, all purchased 
from Life Technologies Inc. 
 Stable MCF7 cell lines were previously prepared by transfecting with pSilencer 
plasmids expressing either shNEGATIVE or shBASP1 as described previously by 
Marsh et al, 201733. Cells were maintained in Dulbecco Modified Eagle Medium 
(DMEM) supplemented with 10% FBS, 1% Pen-Strep and 1% L-Glutamine, all 
purchased from Life Technologies Inc. Positive transfected cells were selected with 




2.3 EZH2 Inhibitors 
UNC1999 was purchased from Cell Signalling Technology and a stock solution of 
5mM in DMSO was made. UNC1999 was used at 3μM concentration.  
GSK343 was purchased from APExBIO and a stock solution of 5mM in DMSO was 
made. GSK343 was used at 5μM concentration.  
GSK126 was purchased from Adoq Bioscience and a stock solution of 5mM in 
DMSO was made. GSK126 was used at 8μM concentration. 
2.4 Growth Assays 
 K562 cells were seeded at approximately 1x105 cells/ml in 10ml RPMI media. Cells 
were treated with either 3μM UNC1999, 5μM GSK343, 8μM GSK126 or the 
equivalent volume of DMSO. Cells were counted every 24 hours for 5 days by mixing 
10μl of cells with 10μl Trypan Blue (Invitrogen). Cells were counted using the 
Countess automated cell counter machine (Invitrogen). 
2.5 Colony Formation Assays 
MCF7 cells were seeded in 6-well plates at approximately 1000 cells in 2ml DMEM 
media. Cells were treated with single and double concentrations of UNC1999 
(3μM/6μM), GSK343 (5μM/10μM) or GSK126 (8μM/16μM) or the equivalent volume 
of DMSO and left for 12 days. Media was replaced every 3 days. At 12 days, the 
media was removed, cells were washed once in 1ml PBS and then left for 10 
minutes in 1ml Methanol (Fisher Scientific). Methanol was then removed and 0.5ml 
of 0.1% Crystal Violet (Sigma Life Science) was added for 5 minutes. 0.1% Crystal 
Violet was made by mixing 1ml 1% Crystal Violet, 3ml Methanol and 6ml H2O. 
Crystal Violet was then washed off and the number of colonies formed was counted 
as well as their size. 
2.6 Nuclear Extracts 
K562 cells were collected, washed in 1ml of PBS per plate and centrifuged at 400g 
for 2 minutes. MCF7 cells were scraped off in 1ml PBS and centrifuged at 1000g for 
2 minutes. PBS was removed and cells were resuspended in 1 estimated packed 
cell volume (PCV) of Nuclear Extract 1 (NE1) buffer and left on ice for 15 minutes. 
NE1 buffer contains 10mM Hepes pH 8, 1.5mM MgCl2, 10mM KCl, 1mM DTT. Cells 




forced out through a 23-gauge needle. This process was repeated 4 times. Cells 
were then centrifuged at 17,000g for 30 seconds, resuspended in 2/3 PCV of 
Nuclear Extract 2 (NE2) buffer and placed on a rotator at 4°C for 30 minutes. NE2 
contains 20mM Hepes pH 8, 1.5mM MgCl2, 25% (v/v) Glycerol, 420mM NaCl, 
0.2mM EDTA, 1mM DTT and 0.5mM Phenylmethylsulfonyl fluoride (PMSF). Cells 
were then centrifuged at 17,000g for 5 minutes and the supernatant was collected as 
the nuclear extract. 
2.7 Western Blotting 
SDS-PAGE gels were made up of a 10% (w/v) acrylamide resolving gel and a 4.5% 
(w/v) acrylamide stacking gel. The gel was then placed in a BIO-RAD Mini-Protean 
Tetra system gel tank (BIORAD) and the tank was filled with SDS-PAGE buffer 
which contains 25mM Tris pH 8.3, 192mM Glycine and 0.1% (w/v) SDS. 10-20ul of 
nuclear extract was loaded into the wells as well as 2μl of Spectra BR marker 
(Thermo Scientific) mixed with 5μl loading dye and 14 μl H2O. The gel was resolved 
at 150V for approximately 1 hour. The proteins were then transferred onto a 
methanol activated Immobilon-P membrane (Merck) in transfer buffer containing 
25mM Tris pH 8.3, 192mM Glycine, 10% (v/v) methanol, using a semi-dry transfer 
cell (BIORAD) running at 25V for 40 minutes. Membrane was then blocked for 1 hour 
in 15ml blocking buffer containing 150mM NaCl, 20mM Tris pH 7.5. 0.1% (v/v) 
Tween and 5% (w/v) dried milk. After blocking, the membrane was left at 4°C 
overnight with the appropriate antibody (Table 2.1) diluted in blocking buffer. The 
following day the membrane was washed 5 times with 10-15ml blocking buffer for 5 
minutes each time. Then the membrane was left rocking for 1 hour at room 
temperature with the appropriate secondary antibody (Table 2.1) diluted in blocking 
buffer. The same washes were repeated before adding Pierce ECL Western Blotting 
Substrate (Thermo Scientific). Protein detection was then done on CL-X PosureTM 





2.8 Gene Expression 
RNA was extracted from K562 and MCF7 cell pellets using a RNeasy Mini Kit 
(Qiagen) and following the manufacturer’s instructions. RNA concentration was then 
measured using a NanoDrop Lite (Thermo Scientific) and diluted to 1ug/ul.  
cDNA was prepared using an iScript cDNA synthesis kit (BIORAD) following the 
manufacturer’s instructions and then using a Techne PCR machine set at 25°C for 5 
minutes, 42°C for 30 minutes and 85°C for 5 minutes the cDNA was prepared.  
q-PCR reactions were set up consisting of 2μl cDNA (prepared as described above 
for RNA extraction and cDNA preparation), 10 μl SYBR Green (BIORAD), 7μl H2O 
and 1 μl Primer stock. Primer stocks for each gene were made up with 50ng/l 
forward primer and 150ng/l reverse primer (Table 2.2). The q-PCR machine was 
set at 95°C for 3 minutes followed by 40 cycles to 95°C for 20 seconds, 60°C for 30 
seconds and 72°C for 30 seconds. To also plot a melt curve, the q-PCR machine 
was set at 95°C for 10 seconds and then 65°C for 5 seconds with the temperature 
then rising by 0.5°C every 5s followed by a plate read each time until the 
temperature reaches 95°C. The melt curves are shown in section 6.1. For AREG, 




Antibody Species  Dilution Source 
BASP1 Rabbit 1:2000 Pacific Immunology, California 
WT1 Rabbit 1:2000 Pacific Immunology, California 
GAPDH Mouse 1:10000 Merck Millipore 
Anti-Rabbit HRP Goat 1:10000 Jackson ImmunoResearch 
Laboratories 
Anti-Mouse HRP Goat 1:10000 Jackson ImmunoResearch 
Laboratories 




2.9 Chromatin Immunoprecipitation (ChIP) 
ChIP Buffers: 
IP Buffer: 150mM NaCl, 50mM Tris-HCl pH 8, 5mM EDTA, 0.5% (v/v) NP-40, 1% 
(v/v) Triton X-100 
High Salt Buffer: 500mM NaCl, 50mM Tris-HCl pH 8, 5mM EDTA, 0.5% (v/v) NP-40, 
1% (v/v) Triton X-100 
LiCl Buffer: 10mM Tris-HCl pH 8, 250mM LiCl, 1mM EDTA, 1% (v/v) NP-40, 1% 
(w/v) Sodium Deoxycholate 
TE Buffer: 10mM Tris-HCl pH 8, 1mM EDTA 
PK Buffer: 125mM Tris-HCl pH 8,10mM EDTA, 150mM NaCl, 1% (w/v) SDS 
K562 cells were harvested and resuspended in Phosphate-buffered saline (PBS) to 
obtain a concentration of 1x106/ml. The cells were then cross-linked by incubating 
with 40μl/ml of PBS of 37% (v/v) formaldehyde for 15 minutes at room temperature 
on a rocker. The cells were then quenched with 141μl/ml of PBS of 1M glycine and 
left for 5 minutes at room temperature on a rocker. The cells were then centrifuged at 
2000g for 5 minutes and the cell pellet was resuspended in 5ml of cold PBS. The 
cells were centrifuged again and resuspended in 1ml IP buffer containing set III 
protease inhibitors (Calbiochem) and left on ice for 15 minutes to lyse. The lysed 
cells were then centrifuged at 2000g for 5 minutes at 4°C and resuspended in 1ml IP 
buffer containing set III protease inhibitors.  
The cells were then sonicated using a QSonica Q500 sonicator set at 50% amplitude 
for 3 seconds ON 2 seconds OFF pulses. This was repeated 16 times for each tube 
PRIMERS Forward Primer 5’-3’ Reverse Primer 5’-3’ 
GAPDH ACAGTCAGCCGCATCTTCTT ACGACCAAATCCGTTGACTC 
AREG TGGATTGGACCTCAATGACA ACTGTGGTCCCCAGAAAATG 
VDR CTGACCCTGGAGACTTTGAG TTCCTCTGCACTTCCTCA 
JUNB TGGTGGCCTCTCTCTACACGA GGGTCGGCCAGGTTGAC 
ETS1 AAACTTGCTACCATCCCGTACGT ATGGTGAGAGTCGGCTTGAGAT 
Table 2.2: Primers used for quantitative PCR 
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of cells. The cells were kept on ice between pulses. The sonicated cells were then 
centrifuged at 12000g for 10 minutes at 4°C and the supernatant was collected and 
mixed with 10μl/ml Mag-G beads (Life Technologies) and left to rotate for 1 hour at 
4°C to preclear the chromatin.  
Successful sonication resulting in the production of 200-500bp fragment was 
confirmed by taking a small sample of the sheared chromatin and de-crosslinking it 
by incubating at 37°C with 30μl PK buffer and 1 μl RNAase A (Abcam) from the 
ab185913 High-Sensitivity ChIP kit, as per manufacturer’s instructions, for 30 
minutes. After 30 minutes 1μl of 20mg/ml Proteinase K (Ambion #AM2546) was 
added and samples left at 62°C for 2 hours to complete de-crosslinking. Samples 
were then loaded onto a 1.5% agarose gel and resolved at 100V for 45 minutes in 
1xTris-acetate-EDTA (TAE) buffer to confirm fragmentation. 
Microtubes containing 600μl IP buffer, 10μl Mag-G beads, 1μl of 10mg/ml acetylated 
BSA (Sigma) and the appropriate antibody (Table 2.3) were previously prepared for 
each ChIP sample and rotated at 4°C for at least 4 hours or overnight. 200 μl of the 
precleared samples was then added to each antibody microtube and left to rotate at 
4°C overnight. 2% of the precleared samples was kept at -20°C for later use. 
The next day, the immunoprecipitated samples were magnetised to remove the 
supernatant and then washed in 1ml of IP buffer and left on ice for 3 minutes. 
Samples were then washed in the same way with 1ml High Salt, with 1ml LiCl buffer 
and TE buffer. Samples, including the 2% inputs, were then resuspended in 100μl 
PK buffer and left at 65°C overnight. The samples were then incubated at 55°C for 3-
4 hours, with 1μl 20mg/ml Proteinase K. The samples were centrifuged at 17000g for 
5 minutes and the DNA in the supernatant purified using a Qiaquick PCR purification 
kit according to the manufacturer’s instructions. The eluted DNA was then heated at 
95°C for 10 minutes and prepared for q-PCR as described in section 2.8 using the 
suitable primers (Table 2.4). The q-PCR machine was set at 95°C for 3 minutes 
followed by 40 cycles of 95°C for 10 seconds, 60°C for 10 seconds and 72°C for 30 
seconds. To also plot a melt curve the q-PCR machine was set up as detailed in 




ChIP Antibody Species Volume per IP Source 
H3K9ac Rabbit 4 μl Abcam #ab10812 
H3K27me3 Mouse 4μl Abcam #ab8898 
Normal IgG Rabbit 1μl  Cell Signalling #2729 
Normal IgG Mouse 1μl Millipore #12-371 
 













ChIP Primer Forward Primer 5’-3’ Reverse Primer 5’-3’ 
18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
AREG TTTAAGTTCCACTTCCTCTCA GGTGTGCGAACGTCTGTA 
JUNB GGTCCTGGTATTTGTCCCAG CTCGCGTCACTGTCAGGAAG 
VDR CACCTGGCTCAGGCGTCC GCCAGGAGCTCCGTTGGC 
ETS-1 CCTAAAGAGGAGGGGAGAGC AGGGGAAGTTGGCACTTTG 
Table 2.3: Antibodies used for ChIP 




3.1 The effect of EZH2 inhibition on cell growth 
3.1.1 Verifying the absence and presence of BASP1 
 The first step of this study was to verify that the cell lines had been stably 
transfected resulting in the production of two derivative cell lines, the V-K562 cells 
and the B-K562 cells. K562 cells express endogenous WT1 but do not express 
BASP1 so the cells had previously been transfected with either an empty vector to 
produce the V-K562 cells or with a vector expressing wild type BASP1 (wtBASP1) to 
produce the B-K562 cells.  Western blots were carried out to confirm the absence of 
BASP1 in V-K562 cells and the presence of BASP1 in B-K562 cells by preparing 
nuclear extracts from the cells. BASP1 was detected at approximately 52kDa only in 
the extract prepared from B-K562 cells as shown in Figure 3.1.  
  
Figure 3.1 also shows the expression of endogenous WT1 in K562 cells. The 
major forms of WT1 migrate as a doublet due to the -17AA and +17AA forms. The B-
K562 cells appear to express more of the +17AA isoform compared to the V-K562 
cells. This was not observed in previous studies of these cells25. It is notable that the 
Figure 3.1: Immunoblots showing the expression of BASP1 in K562 cells. Immunoblots were 
probed for BASP1 and WT1 for V-K562 and B-K562 cells. GAPDH is shown as a loading control. 
Molecular weight markers (kDa) are shown at the left of each immunoblot. 
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slower migrating immunoreactive band in the WT1 blot is also enhanced in the B-
K562 cells compared to the V-K562 cells. This immunoreactive band may be a form 
of WT1 that arises from an upstream translation start site3. 
 The second step of the study was to verify that the treatment of K562 cells 
with the EZH2 inhibitors UNC1999, GSK343 and GSK126 does not alter the 
expression level of BASP1. V-K562 and B-K562 cells were therefore treated with 
either DMSO or an EZH2 inhibitor for 72 hours and nuclear extracts were prepared 
and resolved by SDS-PAGE followed by Western blotting to detect BASP1, as 
shown in Figure 3.2. 
Figure 3.2: Immunoblots showing the expression of BASP1 in K562 cells following treatment 
with EZH2 inhibitors. Immunoblots probed with BASP1 for V-K562 and B-K562 cells treated with 
DMSO, UNC1999 (3μM), GSK343 (5μM) or GSK126 (8μM). Molecular weight markers (kDa) are 
shown at the left of each immunoblot. 
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Figure 3.2 shows that treatment of K562 cells with UNC1999, GSK343 or 
GSK126 does not alter the expression level of BASP1. BASP1 is expressed only in 
B-K562 cells and not in V-K562 cells for cells treated with DMSO or one of the 
inhibitors. The faster migrating band expressed in all cells is non-specific band and 
acts as a loading control. 
A second cell line system was also used for this study, MCF7 cells. MCF7 
cells express endogenous BASP1 and so were previously stably transfected with a 
plasmid driving the expression of either a control shRNA (shNEG) or shRNA directed 
against BASP1 (shBASP1) to produce two derivative cell lines33. The shNEG cells 
which express endogenous BASP1 and the shBASP1 cells where BASP1 is knocked 
down. Western Blots were first carried out to confirm that the cells were stably 
transfected as shown in Figure 3.3.  
 
Figure 3.3 shows that BASP1 was knocked down successfully in shBASP1 
cells however, no loading control was used and so to verify that the same amount of 
protein was loaded for both samples that need to be done. The immunoblot probed 
with BASP1 shows two bands close to the known migration point of BASP1. Based 
on previous studies from the lab, the slower migrating band is a non-specific band 
that has a similar molecular weight to BASP1, and the faster migrating band is 
BASP1 which is present in shNEG cells and knocked down in shBASP1 cells. 
Figure 3.3: Immunoblot showing the expression of BASP1 in MCF7 cells. Immunoblot was 
probed for BASP1 for shNEG and shBASP1 cells. GAPDH is shown as a loading control. Molecular 
weight markers (kDa) are shown at the left of each immunoblot. 
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3.1.2 Evaluation of the effects of EZH2 inhibitors on the growth of K562 cells  
Next, we wanted to study if the inhibition of EZH2 has an effect on the growth 
rate of K562 cells. To measure this, K562 cells were treated with either DMSO or an 
EZH2 inhibitor and then the number of cells was counted every 24 hours for 5 days 
as shown in Figure 3.4.  
 
The three graphs in Figure 3.4 show that V-K562 cells grow faster than B-
K562 cells. This agrees well with previous results, that expression of BASP1 slows 
down K562 cell growth1.Figure 3.4 (A) shows that when treated with UNC1999, K562 
Figure 3.4: EZH2 inhibition effect on the growth of K562 cells. Growth assays were carried out on the K562 cell line 
derivatives following treatment with either DMSO or (A) UNC1999 (M), (B) GSK343 (M) and (C) GSK126 (M). 
The number of cells was measured every 24 hours for 5 days. The y-axis shows the difference in cell number from Day1 
(Dayx-Day1). Significant difference between the effect of DMSO and the EZH2 inhibitor is indicated by *. (B) Significant 
difference between B+DMSO and B+GSK343 (p value=0.0278). (C) Significant difference between V+DMSO and 
V+GSK126 (p value=0.0009) and between B+DMSO and B+GSK126 (p value-=0.0008) 
32 
 
cell growth is decreased in both V-K562 and B-K562 cells, however this effect was 
not found to be significant. Figure 3.4 (B) shows that when K562 cells were treated 
with GSK343 there is slight decrease in the growth rate of V-K562 cells which is not 
significant but there is a significant decrease in growth of the treated B-K562 cells. 
This suggests that GSK343 only has a significant effect on the growth rate of K562 
cells when BASP1 is present. Finally, Figure 3.4 (C) shows that GSK126 significantly 
decreases the growth rate of both V-K562 and B-K562 cells. Taken together these 
results suggest that, overall, the inhibition of EZH2 slows down the growth rate of 
K562 cells and that GSK343 appears to have a greater effect on the growth of K562 
cells when BASP1 is present. 
3.1.3 The effects of EZH2 inhibitors on MCF7 tumorigenicity 
To determine the effect of EZH2 inhibition on MCF7 cell growth, colony 
formation assays were carried out where the cells were either treated with DMSO or 
one of the three inhibitors at two different concentrations. After 12 days the number 
(Figure 3.5 A) and size (Figure 3.5 B) of the colonies present was determined. The 
shBASP1 MCF7 cells showed both an increase in colony number (Figure 3.5 A) and 
average size (Figure 3.4 B) compared to shNEG MCF7 cells. These results are 
consistent with previous studies and are indicative of a tumour suppressor function 












Figure 3.5 A shows the average number of colonies counted after treatment 
with each of the EZH2 inhibitors. With all 3 inhibitors it can be seen that the number 
of colonies decreases as the concentration of the drug increases in both shNEG and 
shBASP1 cells. Figure 3.5 B shows a similar effect of the EZH2 inhibitors on colony 
size where it generally decreases as the inhibitor concentration increases in both 
shNEG and shBASP1 cells.  
Figure 3.5: EZH2 inhibition effect on MCF7 tumorigenicity. (A) Graphs show the average number 
of colonies counted 12 days after MCF7 cells were treated with UNC1999 at 3μM [+] and 6μM 
[++], GSK343 at 5μM [+] and 10μM [++] or GSK126 8μM [+] and 16μM [++]. Cells were also 
treated with DMSO for a control. The number of colonies have been normalised to 
shNEG+DMSO=100. (B) Graphs show the relative average size of the colonies counted in cm.  
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The UNC1999 inhibitor fails to cause a significant decrease in colony number 
or size when used at 3M (+). However, treatment with UNC1999 at 6M (++) 
causes a significant decrease in both colony number and size in both shNEG and 
shBASP1 cells. In MCF7 shBASP1 cells, 6M UNC1999 had a greater effect in 
decreasing the number of colonies (~19-fold) compared to its effect in MCF7 shNEG 
cells where it decreases by ~5-fold. However, the effect of 6M UNC1999 on colony 
size was similar in both MCF7 shNEG and MCF7 shBASP1 cells.  
The GSK343 inhibitor caused a significant decrease in colony number and 
size for both MCF7 shNEG and shBASP1 cells when used at 10M. It also caused a 
significant decrease in colony number in MCF7 shNEG cells when used at 5M. The 
effects of both 5M and 10M GSK434 was similar in both shNEG MCF7 and 
shBASP1 MCF7 cells.  
The GSK126 inhibitor appears to be the most potent of the 3 compounds in 
reducing colony formation of the MCF7 cell derivatives. At 16M the inhibitor 
prevents the formation of any colonies. When used at [8M], GSK126 caused a 
highly significant decrease in the number of colonies present in both shNEG and 
shBASP1 cells, however it did not significantly affect the size of the colonies. Taken 
together these results suggest that inhibition of EZH2 reduces the tumorigenicity of 
the MCF7 cell derivatives by preventing the formation of colonies. While the effects 
were generally observed to be BASP1-independent, UNC1999 was a more effective 
inhibitor of MCF7 colony formation in the absence of BASP1. 
3.2 The effect of EZH2 inhibition on gene expression 
3.2.1 RNA analysis of K562 cells following EZH2 inhibition 
 After establishing the stable transfection of the cells and studying the effect of 
EZH2 inhibition on growth, the next step was to study its effects on transcriptional 
regulation by BASP1/WT1. Four known WT1 target genes were selected to analyse 
because these had been studied before in K562 cells by our lab3,28. The 4 genes are 
AREG, VDR, JUNB and ETS-1. To study the effect of EZH2 inhibition on gene 
expression, K562 cell derivatives were treated with either one of the inhibitors or the 
equivalent amount of DMSO for 72 hours. RNA was then extracted from the cells, 
used to produce cDNA and qPCR was carried out to measure the expression of 
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each of the four genes. GAPDH expression was also measured because it is not a 
WT1 target gene, so it was used as a control. 
 
Figure 3.6 shows the relative expression of AREG, JUNB, VDR and ETS-1 
following the treatment of V-K562 and B-K562 cells with the UNC1999 EZH2 
inhibitor. Previous studies showed that the presence of BASP1 causes repression of 
these genes, as is seen in the V-K562 and B-K562 cells treated with DMSO here16. 
AREG expression is significantly 2.33-fold repressed by BASP1 in untreated B-K562 
cells compared to V-K562 cells. AREG is also repressed by UNC1999, as there is 
decreased gene expression in both treated V-K562 and B-K562 cells compared to 
untreated V-K562 and B-K562 cells. In the presence of UNC1999, AREG is 
Figure 3.6: RNA analysis of K562 cells after treatment with UNC1999. The relative expression of 
AREG, JUNB, VDR and ETS1 compared to GAPDH in V-K562 and B-K562 cells treated with 3μM of 
the EZH2 inhibitor UNC1999 or the equivalent volume of DMSO. Significant differences indicated 
with * for p <0.05 using a Student’s t test. 
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significantly 2.64-fold repressed by BASP1 in treated B-K562 cells compared to 
treated V-K562 cells. This suggests that EZH2 inhibition by UNC1999 does not affect 
the ability of BASP1 to repress transcription of AREG. JUNB expression is 
significantly 2.5-fold repressed by BASP1 in untreated B-K562 cells compared to V-
K562 cells. JUNB is only repressed by UNC1999 in the absence of BASP1 as there 
is a decrease in JUNB expression in treated V-K562 cells compared to untreated V-
K562 cells and an increase in JUNB expression in treated B-K562 cells compared to 
untreated B-K562 cells. In the presence of UNC1999, JUNB is significantly 1.56-fold 
overexpressed by BASP1 in treated B-K562 cells compared to treated V-K562 cells. 
This suggests that BASP1 needs EZH2 to repress the transcription of JUNB. VDR 
expression is significantly 4.53-fold repressed by BASP1 in untreated B-K562 cells 
compared to V-K562 cells. VDR is only repressed by UNC1999 in the absence of 
BASP1 as there is a decrease in VDR expression in treated V-K562 cells compared 
to untreated V-K562 cells and an increase in VDR expression in treated B-K562 cells 
compared to untreated B-K562 cells. In the presence of UNC1999, there is no 
significant change in VDR expression in treated B-K562 compared to treated V-K562 
cells. This suggests that BASP1 needs EZH2 to repress the transcription of VDR. 
ETS-1 expression is significantly 4.17-fold repressed by BASP1 in untreated B-K562 
cells compared to V-K562 cells. ETS-1 is also repressed by UNC1999, as there is 
decreased gene expression in both treated V-K562 and B-K562 cells compared to 
untreated V-K562 and B-K562 cells. In the presence of UNC1999, there is no 
significant change in ETS-1 expression in treated B-K562 cells compared to treated 
V-K562 cells. This suggests that BASP1 needs EZH2 to repress the transcription of 
ETS-1. Taken together these data demonstrate that the treatment of K562 cells with 
UNC1999 abolishes the BASP1-dependent transcriptional repression of JUNB, VDR 







 Figure 3.7 shows the relative expression of AREG, JUNB, VDR and ETS-1 
following the treatment of V-K562 and B-K562 cells with the GSK343 EZH2 inhibitor. 
AREG expression is significantly 6.67-fold repressed by BASP1 in untreated B-K562 
cells compared to V-K562 cells. AREG is also repressed by GSK343, as there is 
decreased gene expression in both treated V-K562 and B-K562 cells compared to 
untreated V-K562 and B-K562 cells. In the presence of GSK343, AREG is 
significantly 3.87-fold repressed by BASP1 in treated B-K562 cells compared to 
treated V-K562 cells. This suggests that EZH2 inhibition by GSK343 does not affect 
the ability of BASP1 to repress transcription of AREG. JUNB expression is 
significantly 1.82-fold repressed by BASP1 in untreated B-K562 cells compared to V-
K562 cells. JUNB is not repressed by GSK343 as there is an increase in JUNB 
expression in treated V-K562 cells compared to untreated V-K562 cells and an 
Figure 3.7: RNA analysis of K562 cells after treatment with GSK343. The relative expression of 
AREG, JUNB, VDR and ETS1 in V- and B-K562 cells treated with 5μM of the EZH2 inhibitor GSK343 
or the equivalent volume of DMSO. Significant differences indicated with * for p <0.05 using a 
Student’s t test. 
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increase in JUNB expression in treated B-K562 cells compared to untreated B-K562 
cells. In the presence of GSK343, JUNB is 1.31-fold overexpressed by BASP1 in 
treated B-K562 cells compared to treated V-K562 cells. This suggests that BASP1 
needs EZH2 to repress the transcription of JUNB. VDR expression is significantly 
3.03-fold repressed by BASP1 in untreated B-K562 cells compared to V-K562 cells. 
VDR is only repressed by GSK343 in the absence of BASP1 as there is a decrease 
in VDR expression in treated V-K562 cells compared to untreated V-K562 cells and 
an increase in VDR expression in treated B-K562 cells compared to untreated B-
K562 cells. In the presence of GSK343, there is no significant change in VDR 
expression in treated B-K562 compared to treated V-K562 cells. This suggests that 
BASP1 needs EZH2 to repress the transcription of VDR. ETS-1 expression is 
significantly 2.63-fold repressed by BASP1 in untreated B-K562 cells compared to V-
K562 cells. ETS-1 is also repressed by GSK343, as there is decreased gene 
expression in both treated V-K562 and B-K562 cells compared to untreated V-K562 
and B-K562 cells. In the presence of GSK343, there is no significant change in ETS-
1 expression in treated B-K562 cells compared to treated V-K562 cells. This 
suggests that BASP1 needs EZH2 to repress the transcription of ETS-1. Thus, the 
treatment of K562 cells with GSK343 abolishes the BASP1-dependent transcriptional 









 Figure 3.8 shows the relative expression of AREG, JUNB, VDR and ETS-1 
following the treatment of V-K562 and B-K562 cells with the GSK126 EZH2 inhibitor. 
AREG expression is 1.92-fold repressed by BASP1 in untreated B-K562 cells 
compared to V-K562 cells. AREG is only repressed by GSK126 in the absence of 
BASP1 as there is a decrease in AREG expression in treated V-K562 cells 
compared to untreated V-K562 cells and a small increase in AREG expression in 
treated B-K562 cells compared to untreated B-K562 cells. In the presence of 
GSK126, AREG is 1.71-fold repressed by BASP1 in treated B-K562 cells compared 
to treated V-K562 cells. The decrease in AREG expression in untreated B-K562 cells 
compared to untreated V-K562 cells and the decrease between treated B-K562 cells 
and treated V-K562 cells is not significant. This suggests that EZH2 inhibition by 
GSK126 does not affect the ability of BASP1 to repress transcription of AREG. JUNB 
Figure 3.8: RNA analysis of K562 cells after treatment with GSK126. The relative expression of AREG, 
JUNB, VDR and ETS1 in V- and B-K562 cells treated with 8μM of the EZH2 inhibitor GSK126 or the 




expression is significantly 1.49-fold repressed by BASP1 in untreated B-K562 cells 
compared to V-K562 cells. JUNB is only repressed by GSK126 in the absence of 
BASP1 as there is a decrease in JUNB expression in treated V-K562 cells compared 
to untreated V-K562 cells and an increase in JUNB expression in treated B-K562 
cells compared to untreated B-K562 cells. In the presence of GSK126, JUNB is 1.22-
fold overexpressed by BASP1 in treated B-K562 cells compared to treated V-K562 
cells. This suggests that BASP1 needs EZH2 to repress the transcription of JUNB. 
VDR expression is significantly 1.89-fold repressed by BASP1 in untreated B-K562 
cells compared to V-K562 cells. VDR is only repressed by GSK126 in the absence of 
BASP1 as there is a decrease in VDR expression in treated V-K562 cells compared 
to untreated V-K562 cells and an increase in VDR expression in treated B-K562 cells 
compared to untreated B-K562 cells. In the presence of GSK126, VDR is 1,51-fold 
overexpressed by BASP1 in treated B-K562 cells compared to treated V-K562 cells. 
This suggests that BASP1 needs EZH2 to repress the transcription of VDR. ETS-1 
expression is significantly 1.67-fold repressed by BASP1 in untreated B-K562 cells 
compared to V-K562 cells. ETS-1 is only repressed by GSK126 in the absence of 
BASP1 as there is a decrease in ETS-1 expression in treated V-K562 cells 
compared to untreated V-K562 cells and an increase in ETS-1 expression in treated 
B-K562 cells compared to untreated B-K562 cells. In the presence of GSK126, there 
ETS-1 is 1.93-fold overexpressed by BASP1 in treated B-K562 cells compared to 
treated V-K562 cells. This suggests that BASP1 needs EZH2 to repress the 
transcription of ETS-1. Thus, the treatment of K562 cells with GSK126 abolishes the 
BASP1-dependent transcriptional repression of JUNB, VDR and ETS-1 but not 
AREG. 
Taken together, the results analysing RNA expression using the inhibitors 
UNC1999, GSK343 and GSK126 show that BASP1 requires EZH2 to carry out its 
transcriptional repression activities on JUNB, VDR and ETS-1. The results also show 
that BASP1 does not need EZH2 to repress the expression of AREG. This suggests 





3.2.2 ChIP analysis of K562 cells following EZH2 inhibition 
 Following RNA analysis experiments, ChIP experiments were carried out to 
test for the presence of H3K27me3 repressive marks and H3K9ac activation marks 
on the promoters of WT1 target genes. For ChIP, the AREG and VDR genes were 
analysed following 48-hour treatment of V-K562 and B-K562 cells with UNC1999 or 
the equivalent volume of DMSO. EZH2 is known to be responsible for placing 
H3K27me3 marks on gene promoters so by treating the cells with an EZH2 inhibitor 
we can study if BASP1 loses its ability to repress genes in the presence of UNC1999 
due to failure of EZH2 to place H3K27me3 marks. H3K9ac marks are not removed 
by EZH2 so inhibition of EZH2 should not have a direct effect on H3K9ac marks. The 
presence of these marks was also measured on BAX which is not a WT1 target gene 




Figure 3.9 shows the relative fold enrichment of H3K27me3 and H3K9ac 
marks at AREG and VDR gene promoters. For AREG, it was observed as expected 
that in untreated B-K562 cells there is a significant increase in H3K27me3 marks and 
a decrease in H3K9ac marks compared to untreated V-K562 cells, corresponding 
with AREG being repressed (however, the latter was not found to be significant). 
When the cells are treated with UNC1999, there is a significant decrease in 
H3K27me3 marks in treated B-K562 cells compared to treated V-K562 cells showing 
that the inhibition of EZH2 prevents H3K27me3 marks from being placed. There is no 
significant change in H3K9ac marks on the promoter of AREG between treated V-
K562 and B-K562 cells, further showing that EZH2 is not involved in the process of 
removing H3K9ac marks. For VDR, there is an increase in H3K27me3 and a 
Figure 3.9: ChIP analysis of K562 cells after treatment with UNC1999. The relative fold enrichment of H3K27me3 
marks and H3K9ac marks compared to BAX on AREG and VDR gene promoters in V- and B-K562 cells treated with 
3μM of the EZH2 inhibitor UNC1999 or the equivalent volume of DMSO for 48 hours. Significant differences 
indicated with * for p <0.05 using a Student’s t test. 
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decrease in H3K9ac marks in untreated B-K562 cells compared to untreated V-K562 
cells, however these changes were not significant. After treatment with UNC1999 
there is a decrease of H3K27me3 marks in both treated V-K562 and B-K562 cells 
suggesting that EZH2 plays a role in placing this histone modification. There is also a 
slight decrease in the level of H3K27me3 marks between treated V-K562 and B-
K562 cells which is in contrast to the BASP1-dependent increase in H3K27me3 in 
untreated cells. Although these changes were not found to pass a significance test, 
they are consistent with BASP1-dependent H3K27 methylation via EZH2. There is 
also no significant change in the levels of H3K9ac marks between treated B-K562 
and V-K562 cells, as was observed at the AREG promoter. 
 Taken together these results suggest that EZH2 is required to place 
H3K27me3 marks on the AREG promoter and that this occurs in a BASP1-
dependent manner. EZH2 is also required to place H3K27me3 marks on the VDR 
promoter and although the data are consistent with BASP1-dependence, the 

















4.1 BASP1 as a growth regulator 
The aim of this study was to establish whether EZH2 is directly involved in the 
BASP1/WT1 transcriptional repressive complex to better understand the mechanism 
by which this complex can repress its target genes. BASP1 has been found to be 
involved in many types of cancer both as a TSG and as an oncogene therefore, 
another part of this study was to determine whether EZH2 can affect the behaviour 
of BASP1 in cancer. Using three EZH2 inhibitors (UNC1999, GSK343 and GSK126) 
and two cell lines (K562 cells and MCF7 cells), growth assays were carried out. In 
K562 cells, BASP1 has been previously shown to act as a TSG gene where the 
expression of BASP1 in K562 cells results in a decreased growth rate of these 
leukaemic cells25. A similar effect is seen in MCF7 cells were the knockdown of 
BASP1 results in an increased growth rate of the cells33. In these two cell lines 
BASP1 is suggested to have a TSG role.  
In K562 cells, treatment with EZH2 inhibitors further decreased the cells’ 
growth rate. Previous studies have suggested that EZH2 can also be involved in 
many cancers as both a TSG and an oncogene and so its inhibition results in a 
decreased growth rate in both V-K562 and B-K562 cells67.  UNC1999 and GSK343 
had a greater effect in decreasing cell growth in the B-K562 cells compared to the V-
K562 cells. These results suggest that EZH2 has an oncogenic role in these cells 
and when inhibited, the role of BASP1 as a TSG can be enhanced to further repress 
tumour growth. With GSK126, both V-K562 and B-K562 cell growth is significantly 
decreased when the cells are treated with the inhibitor. These results suggest that 
GSK126 might not act in a BASP1-dependent manner to decrease cell growth. Since 
GSK126 inhibits EZH2 by the same mechanism as GSK343 they were expected to 
cause similar effects. More experiments are needed with a lower concentration of 
GSK126 to confirm this.  
In MCF7 cells, colony formation assays showed that treatment of the cells 
with the inhibitors resulted in a decrease in both colony number and size suggesting 
that the inhibition of EZH2 results in decreased tumorigenicity of these cells. Colony 
number and size is higher in shBASP1 cells compared to shNEG cells correlating 
with BASP1 having a tumour suppressive role. The effect of EZH2 inhibition in MCF7 
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cells is not BASP1-dependent as the fold changes in colony number and size 
observed in both shNEG and shBASP1 cells are similar. Therefore, the results 
suggest that EZH2 has an oncogenic role in MCF7 cells but BASP1 does not appear 
to be involved in this process.  
 The BASP1/WT1 complex is known to repress many genes involved in both 
cell growth and apoptosis3.  Therefore, gene regulatory mechanisms are likely to be 
at play when EZH2 inhibition causes decreased cell growth in B-K562 cells and 
decreased tumorigenicity in shNEG MCF7 cells. In the presence of EZH2, BASP1 
could potentially repress genes involved in apoptosis, like JUNB and c-MYC84,85, by 
placing H3K27me3 marks. EZH2 was found to be recruited to WT1 target gene 
promoters in a BASP1-dependent manner43. However, coimmunoprecipitation 
experiments failed to demonstrate that BASP1 and EZH2 interact with each other. 
The BASP1 G2A mutant derivative, which is defective in transcriptional repression, 
was still able to mediate recruitment of EZH2 and lead to placement of H3K27me3. 
Thus, H3K27me3 is not sufficient to elicit transcriptional repression of WT1 target 
genes. Whether or not H3K27me3 is required for transcriptional repression by 
BASP1, or EZH2 is the enzyme responsible for its placement, is not clear. The EZH2 
inhibitors were used to determine if this enzyme is required for transcriptional 
repression by BASP1. 
4.2 BASP1 as a gene expression regulator  
The four WT1 target genes analysed were AREG, JUNB, VDR and ETS-1. 
AREG, VDR and ETS-1 are involved in cell growth and development whereas JUNB 
is involved in cell apoptosis84,86–88. Treatment of K562 cells with UNC1999 resulted in 
significant increased JUNB expression in the treated B-K562 cells. In the absence of 
UNC1999, JUNB is normally repressed by BASP1 suggesting that BASP1 requires 
EZH2 to be able to repress JUNB. The increase in JUNB expression in treated B-
K562 cells could potentially result in increased apoptosis which may explain why the 
treated B-K562 cells also have a decrease in cell growth. The same effect on JUNB 
is observed with inhibitors GSK343 and GSK126, however the increase in JUNB 
expression is not significant and more experiments are needed to confirm this.  
 AREG, which is a growth factor, remains significantly repressed in B-K562 
cells treated with UNC1999 and GSK343. It also appears to remain repressed in B-
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K562 cells treated with GSK126, but this was not found to be significant. AREG is a 
growth factor and thus its repression further correlates with the decrease in cell 
growth observed in treated K562 cells. These results also suggest that BASP1 has a 
different mechanism for repressing AREG and JUNB, since BASP1 can still repress 
AREG under conditions of EZH2 inhibition whereas it cannot repress JUNB. EZH2 is 
known to place H3K27me3 marks however, as mentioned in section 1.2.4, on WT1 
target genes additional repressive H3K9me3 marks have also been found as well as 
BASP1-dependent removal of H3K9ac and H3K4me3 activatory marks28,43. 
Therefore, H3K27me3 marks alone do not repress AREG since by inhibiting EZH2, 
H3K27me3 marks are not placed and AREG is still repressed. ChIP analysis of 
H3K27me3 marks and H3K9ac marks on the promoter of AREG revealed that there 
is indeed a significant decrease in the levels of H3K27me3 in B-K562 cells treated 
with UNC1999 compared to treated V-K562 cells. This further confirms that EZH2 is 
responsible for placing H3K27me3 on AREG and that the placement of H3K27me3 
marks is not required for transcriptional repression of AREG. The levels of H3K9ac 
marks do not change significantly between treated V-K562 and B-K562 cells as 
expected. More ChIP experiments would need to done analysing the levels of other 
activatory and repressive marks on AREG in order to determine the reasons that 
AREG remains repressed. 
 VDR and ETS-1 are both genes involved in development. They both appear 
to be affected by EZH2 inhibition in the same way. For both VDR and ETS-1, BASP1 
caused robust transcriptional repression that was disrupted by the EZH2 inhibitors. 
This suggests that EZH2 enzymatic activity is required for BASP1 to repress these 
genes. These results differ from the results observed with AREG and JUNB 
suggesting that the mechanism of BASP1-mediated transcriptional repression 
depends on the target gene. ChIP analysis for VDR showed that there was no 
significant difference in the levels of H3K27me3 marks between V-K562 and B-K562 
cells treated with UNC1999. There does however seem to be a decrease of 
H3K27me3 marks in both treated V-K562 and B-K562 cells compared to untreated 
V-K562 and B-K562 cells. This suggests that EZH2 can place H3K27me3 marks on 
VDR independently of BASP1 in both V-K562 and B-K562 cells. There is no 
significant difference in the levels of H3K9ac marks between treated V-K562 and B-
K562 cells as expected. 
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 Taken together, the results suggest that the BASP1/WT1 complex and EZH2 
work together to repress target genes by placing H3K27me3 marks, however the 
mechanism is not the same for all genes. Figure 4.1 suggests two different 
mechanisms by which the BASP1/WT1 complex behaves, based on the results from 
the AREG and VDR genes (where both RNA and ChIP analysis was performed). At 
the AREG promoter BASP1 recruits EZH2 to methylate H3K27. When EZH2 is 
inhibited by UNC1999, methylation of H3K27 is reduced but the AREG gene is still 
repressed. At the VDR promoter the same EZH2 mechanism is at play, but the 
reduced H3K27 methylation in the presence of UNC1999 blocks BASP1-dependent 
repression of the gene. JUNB and ETS-1 likely function in a similar way to VDR, but 
ChIP analysis will be required to confirm this.  
 
JUNB appears to be the gene most affected by EZH2 inhibition and this may 
be involved in the reduced growth rate of K562 cells. This could suggest a future 
therapeutic target of JUNB via EZH2 inhibition for CML patients. The results also 
suggest that the removal of the H3K27me3 marks from WT1 target gene promoters 
is not sufficient to reverse the repression from some of its target genes and so 
Figure 4.1: Proposed mechanism of BASP1/WT1-EZH2 mediated repression.  The figure shows 
the promoter regions of the AREG and VDR genes. The BASP1/WT1 complex recruits EZH2 which 
places H3K27me3 marks resulting in gene repression. When EZH2 is inhibited by UNC1999 
(indicated by the blue triangle), the levels of H3K27me3 are decreased. AREG is repressed in the 
presence of UNC1999 whereas VDR is expressed.  
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further research into the other activatory and repressive marks found on the 
promoter regions of these genes could give further insight into the mechanism of 
BASP1/WT1 mediated transcriptional repression.  
Despite the results suggesting that BASP1 and EZH2 work together, there 
has been no evidence provided so far showing that the two proteins interact, as 
mentioned previously. Therefore, the recruitment of PRC2 to the promoter of WT1 
target genes, and therefore EZH2, could be dependent on a variety of other factors. 
The overall mechanism of PRC2 recruitment is not known but there have been many 
suggested mechanisms. One proposed mechanism suggests that the mono-
ubiquitylation of lysine 199 on histone H2A (H2AK119ub1) by PRC1 leads to the 
recruitment of PRC2 by binding to the JARID2 subunit of the PRC2.2 complex89. 
Evidence has also been found that the PRC2 product, H3K27me3 marks, can also 
recruit PRC247. EZH2 is activated by H3K27me3 binding to the core PRC2 subunit 
EED which leads to the ‘spreading’ of H3K27me3 marks and thus maintains the 
transcriptionally silent state of the gene. Studies have shown that RNA can be 
involved in the chromatin remodelling process and sometimes even have the ability 
to recruit chromatin remodelling factors90.  The non-coding RNA (ncRNA) HOTAIR 
which is transcribed form the HOXC locus was found to drive the recruitment of 
PRC2 at the HOXD loci91. The HOX genes are involved in the development process, 
which BASP1 and WT1 are also involved in therefore this could be the mechanism of 
PRC2 recruitment of BASP1. Recent studies however have shown that HOTAIR-
mediated repression can also occur independent of PRC2 and so the role of ncRNAs 
in PRC2 recruitment is not yet clear92. More recently, nascent RNA was found to 
bind to PRC2 and prevent PRC2 from interacting with the chromatin by acting as an 
antagonist93. This data corresponds with PRC2 being recruited to repressed genes 
to maintain their transcriptionally silent state. 
Studies have also found that the presence of active chromatin marks, such as 
H3K4me3 which are found on WT1 target genes, can inhibit the recruitment of 
PRC294. Therefore, the removal of active chromatin marks by the BASP1/WT1 
complex through HDAC1 and Prohibitin could enable the recruitment of PRC2 to 
these genes. However, studies using the G2A-BASP1 which is not myristoylated and 
therefore cannot remove active chromatin marks from gene promoters showed that, 
EZH2 can still be recruited to the gene promoter region and place H3K27me3 marks. 
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Therefore, this proposed mechanism of PRC2 recruitment could not apply for WT1 
target genes. As mentioned in section 1.2.5, the target genes of WT1 are bivalent so 
they can have both active and repressive chromatin marks found on the promoter 
region. This could explain why the AREG gene is being repressed even when the 
level of H3K27me3 marks decreases. The additional repressive marks found on the 
AREG promoter, such as H3K9me3, could be sufficient to repress AREG. The 
removal of active chromatin marks by BASP1 could also be sufficient to repress 
AREG. Further experiments with the G2A-BASP1 could show why the H3K27me3 
marks are not enough to repress AREG. Further research into BASP1-dependent 


















5.1 Validating the role of EZH2 in the BASP1/WT1 complex 
ChIP experiments in this study were only performed on the AREG and VDR 
genes using the UNC1999 inhibitor. Therefore, ChIP experiments also need to be 
performed on the JUNB and ETS-1 genes and with the GSK343 and GSK126 
inhibitors to establish if the same pattern is seen with all three inhibitors. Gene 
expression analysis and ChIP experiments should also be carried out in MCF7 cells 
using the same genes and inhibitors to determine if the same effect occurs in a 
different cell line. To validate the results found using the EZH2 inhibitors, siRNA 
targeting EZH2 can be used to ensure that the specific inhibition of EZH2 is the 
cause for the results observed. CRISPR-Cas9-mediated knockout of EZH2 can also 
be used however, recent studies showed that CRISPR-Cas9 EZH2 knockout results 
in decreased cell viability in neuroblastoma cells95.  
5.2 The role of PRC2 in the BASP1/WT1 complex  
Inhibition of other PRC2 core subunits such as EED, SUZ12 and RBBP46/48 
followed by WT1 target gene expression analysis and ChIP should also be done to 
establish if the whole PRC2 complex is involved in BASP1/WT1 mediated repression. 
Analysis of other chromatin marks found on WT1 target gene promoters, like 
H3K9me3 and H3K4me3, should be performed using ChIP experiments to show how 
the levels of other activatory or repressive marks change when the genes are 
repressed by BASP1. The mechanism by which PRC2 is recruited by BASP1 can be 
studied by targeting active histone marks known to inhibit PRC2 recruitment.  
5.3 The role of chromatin remodelling factors in the BASP1/WT1 complex  
Previous Mass Spectrometry experiments by our lab showing BASP1-binding 
proteins identified several chromatin remodelling proteins such as KDM4B and 
NSD343. KMD4B (also known as JMJD2B) is a histone demethylase protein shown to 
be involved in the removal of methyl groups from H3K9, one of the repressive marks 
found on WT1 target genes96. NSD3 is a histone methyltransferase found to be 
involved in the methylation of H3K27 and H3K4, repressive and activatory marks 
respectively found on WT1 target genes97. ChIP experiments can therefore be carried 
out to study if these proteins are being recruited by BASP1 like EZH2. If these proteins 
are being recruited by BASP1, further experiments using siRNA and inhibitors 
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targeting these proteins can be carried out in a similar way to the experiments carried 
out in this study for EZH2.  
5.4 Role of EZH2 in podocyte development 
 Conditional knockout studies of WT1 in podocyte cells have shown that loss of 
WT1 results in the loss of foot processes in the podocyte cells which leads to death 
caused by severe kidney failure98. This showed that WT1 expression is essential in 
the kidney of the adult mouse. Conditional knockout studies of EZH2 in podocyte cells 
could show if EZH2 is necessary for normal kidney function. Such findings would be 
consistent with a role for EZHh2 in BASP1/WT1 function in podocyte cells. Follow-up 
experiments to demonstrate a functional interaction, such as ChIP and RNA analysis, 




















6.1 Melt Curves for RNA analysis 
When samples were analysed on a qPCR machine to study the levels of gene 
expression, melt curves were also made as explained in section 2.8. the melt curves 
indicated a single peak were the double-stranded DNA primer would break and the 
fluorescence from SYBR green could be measured. The melt curved validated that 
the samples were not contaminated by any non-specific DNA products. The melt 
curves are shown in Figures 6.1, 6.2 and 6.3. 
 
Figure 6.1: Melt curves for RNA analysis of K562 cells with UNC1999. Melt curve analysis of the 
AREG, JUNB, VDR and ETS-1 genes following 72h treatment with UNC1999 in K562 cells. Peak 














Figure 6.2: Melt curves for RNA analysis of K562 cells with GSK343. Melt curve analysis of the 
AREG, JUNB, VDR and ETS-1 genes following 72h treatment with GSK343 in K562 cells. Peak 















Figure 6.3: Melt curves for RNA analysis of K562 cells with GSK126. Melt curve analysis of the 
AREG, JUNB, VDR and ETS-1 genes following 72h treatment with GSK126 in K562 cells. Peak 




6.2 DNA gel for sonication analysis 
A DNA gel was run after cells were sonicated for ChIP experiments as explained in 
section 2.9. this was done to validate that the DNA in the cells was successfully 
sheared to produce small DNA fragments between 200 and 500 base pairs. The 









Figure 6.4: DNA gel showing successful sonication of K562 cells. Gel electrophoresis following 




6.3 Melt Curves for ChIP analysis 
Melt curves made in the same way as explained in section 6.1. Melt curves for ChIP 










Figure 6.5: Melt curves for ChIP analysis of K562 cells with UNC1999. Melt curve analysis of the 
AREG and VDR genes following 48h treatment with UNC1999 in K562 cells. Peak indicates the 
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